- Home
- GLAD vs CSTL Comparison
GLAD vs CSTL Comparison
Compare GLAD & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- CSTL
- Stock Information
- Founded
- GLAD 2001
- CSTL 2007
- Country
- GLAD United States
- CSTL United States
- Employees
- GLAD N/A
- CSTL N/A
- Industry
- GLAD Finance/Investors Services
- CSTL Medical Specialities
- Sector
- GLAD Finance
- CSTL Health Care
- Exchange
- GLAD Nasdaq
- CSTL Nasdaq
- Market Cap
- GLAD 547.5M
- CSTL 568.2M
- IPO Year
- GLAD N/A
- CSTL 2019
- Fundamental
- Price
- GLAD $25.42
- CSTL $20.63
- Analyst Decision
- GLAD Hold
- CSTL Strong Buy
- Analyst Count
- GLAD 1
- CSTL 6
- Target Price
- GLAD $23.00
- CSTL $40.00
- AVG Volume (30 Days)
- GLAD 144.4K
- CSTL 372.7K
- Earning Date
- GLAD 05-06-2025
- CSTL 05-05-2025
- Dividend Yield
- GLAD 9.36%
- CSTL N/A
- EPS Growth
- GLAD 60.05
- CSTL N/A
- EPS
- GLAD 4.63
- CSTL 0.62
- Revenue
- GLAD $95,360,000.00
- CSTL $332,069,000.00
- Revenue This Year
- GLAD N/A
- CSTL N/A
- Revenue Next Year
- GLAD $10.81
- CSTL $3.34
- P/E Ratio
- GLAD $5.49
- CSTL $33.76
- Revenue Growth
- GLAD 5.53
- CSTL 51.09
- 52 Week Low
- GLAD $20.85
- CSTL $16.97
- 52 Week High
- GLAD $30.43
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- GLAD 48.73
- CSTL 48.89
- Support Level
- GLAD $23.85
- CSTL $20.26
- Resistance Level
- GLAD $25.20
- CSTL $22.82
- Average True Range (ATR)
- GLAD 1.07
- CSTL 1.31
- MACD
- GLAD 0.18
- CSTL 0.24
- Stochastic Oscillator
- GLAD 98.58
- CSTL 58.97
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.